Results 281 to 290 of about 179,498 (360)

Multimodal gene and targeted drug therapy for chronic myelogenous leukemia using BIM/MCL-1 chimeric nanoparticle: computational target analysis and therapeutic validation. [PDF]

Nano Converg
Lugin ML, Lei W, Lee RT, Chung JY, Katritsis NM, Hwang W, Fleischman AG, Han N, Kwon YJ.   +8 more
europepmc   +1 more source

Recurrent Genomic Alterations in BCRi‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up

American Journal of Hematology, Volume 101, Issue 7, Page 1516-1521, July 2026.
Jennifer A. Woyach, Relja Popovic, Emily L. Rossi, Sanjana Singh, Toshihiko Oki, Tanya S. Rosenberg, Chen Qian, Michael Moran, Zihuan Liu, Michelle Boyer, Jeffrey Jones, Richard R. Furman, William Wierda, Jason Gotlib, Stephen J. Schuster, Brenda Chyla, Matthew S. Davids   +16 more
wiley   +1 more source

Site-specific profiling of structure and function of Igµ B cell receptor glycans. [PDF]

Nat Commun
Holborough-Kerkvliet MD, Hafkenscheid L, Kroos S, Biersteker R, van de Wetering R, Singh O, Fadda E, Tjokrodirijo RTN, van Veelen PA, Wuhrer M, Falck D, Toes REM.   +11 more
europepmc   +1 more source

Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches. [PDF]

Cancers (Basel)
Khazaei Z, Pouliot F, Archambault L.
europepmc   +1 more source

Targetable Vulnerabilities in MYC-Driven B Cell Lymphomas Resistant to BCR Extinction. [PDF]

Hematol Oncol
Brambillasca S, Parr NC, Palmeri A, Andronache A, Arima H, Faga' G, Leuzzi B, Perucho L, Robusto M, Pasi M, Mainoldi F, Fancelli D, Varasi M, Varano G, Mercurio C, Casola S.   +15 more
europepmc   +1 more source

How Epstein–Barr Virus Drives Multiple Sclerosis: New Mechanisms and Therapeutic Lessons

MedComm, Volume 7, Issue 7, July 2026.
Dan Liu, Wenhui Fan, Pengtao Jiao
wiley   +1 more source

Left inferior vena cava - when an anatomical variation has surgical implications. [PDF]

BMJ Case Rep
Palmeira B, Gomes M, Teixeira M, Pires M.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.

Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis, 2020
Asciminib is a potent, orally bioavailable, investigational drug that specifically and potently inhibits the tyrosine kinase activity of native ABL1, together with that of the chimeric BCR-ABL1 oncoprotein which causes chronic myeloid leukemia (CML).
P. Manley, Louise Barys, S. Cowan-Jacob
semanticscholar   +1 more source

Mechanisms of resistance to BCR–ABL TKIs and the therapeutic strategies: A review

Critical Reviews in Oncology/Hematology, 2015
Liwu Fu
exaly   +2 more sources